New perspective of the treatment of Helicobacter pylori infection;Nowe możliwości leczenia zakażenia Helicobacter pylori

Przeglad Gastroenterologiczny

Volumn 6, Issue 6, 2011, Pages 364-369

  Iwańczak, Franciszek ^a   Iwańczak, Barbara ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Compliance; Eradication; Helicobacter pylori; Resistance; Sequential therapy

Indexed keywords

ANTIINFECTIVE AGENT; BISMUTH; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; DRUG EFFICACY; HELICOBACTER INFECTION; HUMAN; PATIENT COMPLIANCE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 83055169159     PISSN: 18955770     EISSN: 18974317     Source Type: Journal    
DOI: 10.5114/pg.2011.25991     Document Type: Review

References (34)

1. Marshall BJ, Warren JR. Unidentified cerved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-5.
2. Moyaert H, Franceschi F, Roccavina D, et al. Extragastric manifestations of Helicobacter pylori infection: other Helicobacters. Helicobacter 2008; 13 (Suppl 1): 47-57.
3. Gonciarz M, Włoch M, Gonciarz Z. Helicobacter pylori in liver diseases. J Physiol Pharmacol 2006; 57 (Suppl 3): 155-61. (Pubitemid 44617517)
4. Malfertheiner P, Mégraud F, O'Morain, et al. The European Helicobacter study Group (EHSG): current concept in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81. (Pubitemid 46854190)
5. Dzieniszewski J, Jarosz M; Grupa Robocza PTG-E do spraw zakażenia Helicobacter pylori. Ustalenia Grupy Roboczej PTG-E dotycza̧ce postȩpowania w zakażeniu Helicobacter pylori - Consensus 2008. Gastroenterol Pol 2008; 15: 323-31.
6. Koletzko S, Jonem NL, Goodman K, et al. Evidence-based recommendations from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenter Nutr 2011; 53: 230-43.
7. Suzuki T, Matsuo K, Ito H, et al. Smoking increases failure for Helicobacter pylori eradication. Am J Med 2006; 119: 217-24. (Pubitemid 43255059)
8. Mégraud F. H. pylori antibiotic resistance: prevalence, importance and advances in testing. Gut 2004; 53: 1374-84.
9. Koletzko S, Richy F, Bontems P, et al. Prospective multicenter study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006; 55: 1711-6. (Pubitemid 44893567)
10. Dzierżanowska-Fangart K, Rożynek E, Celińska-Cedro D, et al. Antimicrobial resistance of Helicobacter pylori In Poland: a multicentre study. Int J Antimicrob Agents 2005; 26: 230-4. (Pubitemid 41219609)
11. Łaszewicz W. Wyniki badań nad zakażeniem Helicobacter pylori. Trans Humana Białystok 2004.
12. Gościniak G, Iwańczak B, Przondo-Mordarska A i wsp. Ocena wrażliwości szczepów Helicobacter pylori na wybrane chemioterapeutyki. Pediatr Pol 2001; 76: 873-7.
13. Gościniak G. Rodzaj Helicobacter pylori - implikacje kliniczne i narastaja̧cy problem oporności. Pediatr Współcz Gastroenterol Hepatol Żyw Dz 2010; 12: 41-4.
14. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple firstline therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-57. (Pubitemid 47063149)
15. Qasim A, Sebastian S, Thornton O, et al. Rifabutin-and furazolidone- based Helicobacter pylori eradication therapies after failure of standard first-and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21: 91-6. (Pubitemid 40175349)
16. Liou JM, Lin JT, Chang CY, et al. Levofloxacin-based and clarithromycin- based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 2010; 59: 572-8.
17. Sacco F, Spezzaferro M, Amitrano M, et al. Efficacy of four different moxifloxacin-based triple therapies for first-line H. py lori treatment. Dig Liver Dis 2010; 42: 110-4.
18. Luther J, Higgins PD, Schoenfeld PS, et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65-73.
19. van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324: 1306-7. (Pubitemid 34606771)
20. Podlewski JK, Chwalibogowska-Podlewska A. Leki współczesnej terapii. Split Trading Sp. z o.o., Warszawa 2005; 433.
21. Zagari RM, Bianchi-Porro G, Fiocca R, et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007; 56: 475-9. (Pubitemid 46580501)
22. Filipec Kanizaj T, Katicic M, Skurla B, et al. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Helicobacter 2009; 14: 29-35.
23. Malfertheiner P, Mégraud, Giguere M, Riviere M. Quadruple therapy with bismuth subcitrate potassium, metronidazole, tetracycline and omeprazole is superior to triple therapy with omeprazole, amoxicillin, and clarithromycin in the eradication of Helicobacter pylori. Gastroenterology 2010; 138 (Suppl 1): S-33 (Abstract).
24. Chey WD, Wong BC. American College of Gastroenterology guideline on the managemant of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25. (Pubitemid 47206706)
25. Lee M, Kemp JA, Canning E, et al. A randomized controlled trial of an enhanced patient complicance program for Helicobacter pylori therapy. Arch Intern Med 1999; 159: 2312-6. (Pubitemid 29501531)
26. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-6.
27. Gisbert JP, Calvet X, O'Connor A, et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44: 313-25.
28. Iwańczak B, Iwańczak F, Potyrała M i wsp. Ocena skuteczności leczenia zakażenia Helicobacter pylori u dzieci. Pediatr Pol 2001; 76: 867-72.
29. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010; 8: 36-41.
30. Paoluzi OA, Visconti E, Andrei F, et al. Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol 2010; 44: 261-6.
31. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regiment for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010; 31: 1077-84.
32. Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104: 3069-79.
33. Dzierżanowska D. Lekooporność Helicobacter pylori i co z tego wynika. III Białostockie Dni Gastroenterologii. Algorytmy postȩpowania. Białystok 2008.
34. O'Conor A, Gisbert JP, McNamara D, et al. Treatment of Helicobacter pylori infection 2010. Helicobacter 2010; 15 (Suppl 1): 46-52.